REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that management will present at the following investor conferences next month:
| Jefferies 2015 Global Healthcare Conference |
| June 2, 2015 at 10:30 a.m. Eastern Time |
| New York, N.Y. |
| William Blair 35th Annual Growth Stock Conference |
| June 9, 2015 at 10:50 a.m. Central Time |
| Chicago, Ill. |
The presentations will be webcast live and available for replay from ZS Pharma's website at http://www.zspharma.com in the Investor Relations section. A replay of the webcasts will be available on the Company's website for 30 days following the live event.
About ZS Pharma
ZS Pharma is a publicly traded (Nasdaq:ZSPH), biopharmaceutical company with offices in Redwood City, California and Coppell, Texas. ZS Pharma's lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information about ZS Pharma is available at www.zspharma.com.